Remission Induction by Arsenic Trioxide in Patient with Relapsed Acute Promyelocytic Leukemia after Allogeneic Bone Marrow Transplantation.
- Author:
Hae Jeong SONG
1
;
Nam Su LEE
;
So Eun KIM
;
Chan Kyu KIM
;
Gyu Taeg LEE
;
Sung Gyu PARK
;
Jong Ho WON
;
Seung Ho BAICK
;
Dae Sik HONG
;
Hee Sook PARK
Author Information
1. Division of Hematology Oncology, Department of Internal Medicine, Soon Chun Hyang University College of Medicine, Seoul, Korea.
- Publication Type:Case Report ; Clinical Trial
- Keywords:
Acute promyelocytic leukemia;
Arsenic trioxide
- MeSH:
Adult;
Arsenic*;
Bone Marrow Transplantation*;
Bone Marrow*;
China;
Diagnosis;
Drug Therapy;
Female;
Humans;
Leukemia, Promyelocytic, Acute*;
Liver;
Lymphocytes;
Recurrence;
Remission Induction*;
Tissue Donors;
Tretinoin;
United States
- From:Korean Journal of Hematology
2002;37(3):218-222
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
All-trans retinoic acid (ATRA) therapy induces complete remission in acute promyelocytic leukemia (APL) via differentiation of the APL cells. Recent clinical trials in China and United states showed that arsenic trioxide (ATO) is an effective and relatively safe drug in the treatment of APL. The patient was 29-year-old woman with APL who had been treated heavily with allogeneic bone marrow transplantation (BMT) in 4 years ago and reinduction chemotherapy plus donor lymphocyte infusion (DLI) after relapse in 2 years ago. After diagnosis for relapse, she had been treated with ATRA, but unfortunately failed. She was treated with ATO at the dose of 10 mg/day intravenously for 6 weeks. Complete remission was achieved at 3 weeks and the cumulative dose of ATO during induction was 420mg. She had complete remission without severe adverse effects except mild impairment of liver function and is following up for 6 months. We report a case of remission induction by ATO in ATRA refractory APL patient who experienced multiple relapse after allogeneic BMT, chemotherapy and DLI.
